We acknowledge financial support from NIH (U01-CA151455 and U54-119343). We would like to thank Kathryn deKrafft, Asif Khan, and Honorio Lara for experimental help and acknowledge technical support from the UNC Animal Studies Core.
Polysilsesquioxane Nanoparticles for Targeted Platin-Based Cancer Chemotherapy by Triggered Release†
Article first published online: 14 SEP 2011
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 50, Issue 44, pages 10330–10334, October 24, 2011
How to Cite
Della Rocca, J., Huxford, R. C., Comstock-Duggan, E. and Lin, W. (2011), Polysilsesquioxane Nanoparticles for Targeted Platin-Based Cancer Chemotherapy by Triggered Release . Angew. Chem. Int. Ed., 50: 10330–10334. doi: 10.1002/anie.201104510
- Issue published online: 18 OCT 2011
- Article first published online: 14 SEP 2011
- Manuscript Received: 29 JUN 2011
- NIH. Grant Numbers: U01-CA151455, U54-119343
- antitumor agents;
- drug delivery;
Trigger happy: Polysilsesquioxane (PSQ) nanoparticles that contain a PtIV-based active agent (1; see picture) can be used for the triggered delivery of chemotherapeutics. The cytotoxicity of 1 was superior to that of oxaliplatin against four cancer cell lines in vitro, and targeting further enhanced the cytotoxicity. PEGylated and anisamide-targeted 1 showed drastically superior efficacy to oxaliplatin in inhibiting tumor growth.